VistaGen TherapeuticsVTGN
VTGN
About: Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Employees: 57
0
Funds holding %
of 7,429 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
499% more call options, than puts
Call options by funds: $437K | Put options by funds: $73K
55% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 11
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
2% more funds holding
Funds holding: 49 [Q1] → 50 (+1) [Q2]
2.5% less ownership
Funds ownership: 55.24% [Q1] → 52.74% (-2.5%) [Q2]
23% less capital invested
Capital invested by funds: $39M [Q1] → $30.1M (-$8.98M) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for VTGN.
Financial journalist opinion
Based on 5 articles about VTGN published over the past 30 days
Neutral
Seeking Alpha
2 weeks ago
Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q1 2026 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Joshua S. Prince - Chief Operating Officer Mark Adrian McPartland - Senior Vice President of Investor Relations Shawn K.
Positive
The Motley Fool
2 weeks ago
Vistagen (VTGN) Q1 R&D Expense Jumps 54%
Vistagen (VTGN) Q1 R&D Expense Jumps 54%
Neutral
Zacks Investment Research
2 weeks ago
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.35 per share a year ago.
Neutral
Business Wire
2 weeks ago
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2026 first quarter ended June 30, 2025, and provided a corporate update. “We had another productive quarter, advancing key programs across our pipeline,” said Shawn Singh, Presid.
Neutral
Business Wire
3 weeks ago
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2026 first quarter ended June 30, 2025, and provide a.
Neutral
Business Wire
1 month ago
Vistagen to Present at the BTIG Virtual Biotechnology Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, July 29, at 10 a.m. Eastern Time. The Fireside Chat will be lives.
Neutral
Business Wire
1 month ago
Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, has earned two prestigious workplace honors in 2025, reinforcing its commitment to employee well-being and a strong, values-driven culture. For the third consecutive year, Vistagen received Mental Health America's Platinum Bell Sea.
Neutral
Business Wire
2 months ago
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead the evaluation of strategic opportunities to advance Vistagen's pherine platform toward potential commercial la.
Neutral
Seeking Alpha
2 months ago
Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript
Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q4 2025 Earnings Conference Call June 17, 2025 5:00 PM ET Company Participants Cynthia Lynn Anderson - VP & Chief Financial Officer Mark Adrian McPartland - Senior Vice President of Investor Relations Shawn K. Singh - President, CEO & Director Conference Call Participants Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Lin Tsai - Jefferies LLC, Research Division Myles Robert Minter - William Blair & Company L.L.C.
Neutral
Business Wire
2 months ago
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2025, and provided a corporate update. “This was a defining year for Vistagen, marked by significant progress in our registration-directed PALISADE program for fa.
Charts implemented using Lightweight Charts™